在ACOSOG Z0011试验中代表性不足的患者是否仍需完成腋窝淋巴结清扫?
该回顾性研究纳入105例在Z0011试验中代表性不足或排除的乳腺癌患者,均行肿块切除加前哨淋巴结活检阳性但未行腋窝淋巴结清扫并完成辅助放疗。4年无病生存率94.3%、局部区域控制率98.1%,无腋窝或同侧乳腺肿瘤复发。作者认为完成腋窝淋巴结清扫或可安全省略,但需更大数据集和更长随访确认。
要点
- 105例Z0011试验代表性不足患者行肿块切除加前哨淋巴结活检阳性未行腋窝淋巴结清扫并辅助放疗,4年无病生存率94.3%、局部区域控制率98.1%。
- 全组无腋窝或同侧乳腺肿瘤复发,1例内乳淋巴结复发、1例对侧乳腺肿瘤、2例远处转移。
- 作者认为完成腋窝淋巴结清扫或可安全省略,但需更大数据集和更长随访确认。
核心结论
- 该回顾性分析显示,在Z0011试验中代表性不足或排除、行肿块切除加前哨淋巴结活检阳性并完成辅助放疗的乳腺癌患者,局部区域控制率和无病生存率与Z0011试验相当。
- 作者认为完成腋窝淋巴结清扫或可安全省略,但需更大数据集和更长随访时间确认。
研究设计与样本
- 回顾性研究,纳入2011年7月至2016年7月间接受治疗的105例女性乳腺癌患者,中位随访48.5个月(范围11-83个月)。
- eligible患者需满足以下之一:T3肿瘤、前哨淋巴结阳性数>2枚、浸润性小叶癌、雌激素受体阴性、结外延伸、诺丁汉分级3级或年龄<50岁。
- 所有患者均行肿块切除加前哨淋巴结活检阳性但未行腋窝淋巴结清扫,并完成辅助放疗。
主要发现
- 40例(38.9%)有结外延伸,42例(40.0%)为分级3级疾病。
- 19例(18.1%)仅接受全乳腺照射,86例(81.9%)接受改良切线野包括腋窝I/II级,其中33例(31.4%)还接受第3个锁骨上淋巴结定向野。
- 86例接受腋窝淋巴结照射的患者中,77例(89.5%)进行了淋巴结体积勾画。
- 51例(48.6%)还接受辅助化疗。
- 4年无病生存率和局部区域控制率分别为94.3%和98.1%;全组1例内乳淋巴结复发、1例对侧乳腺肿瘤、2例远处转移,无腋窝或同侧乳腺肿瘤复发。
关键数值与推荐
- 4年无病生存率为94.3%,局部区域控制率为98.1%。
- 全组无腋窝或同侧乳腺肿瘤复发。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为回顾性分析。
- 需更大数据集和更长随访时间确认该发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The American College of Surgeons Oncology Group trial Z0011 demonstrated that axillary node dissection (ALND) can be omitted in patients managed with breast conserving surgery and 1 to 2 positive sentinel lymph nodes (SLNs) without adverse effects on locoregional recurrence or disease-free survival (DFS). We investigated patients with breast cancer for whom clinicopathologic features were underrepresented in the Z0011 trial and analyzed radiation therapy treatment patterns and clinical outcomes. METHODS AND MATERIALS: We retrospectively reviewed records of patients who underwent a lumpectomy and SLN biopsy with positive SLNs but not an ALND and completed adjuvant radiation therapy. Eligible patients had T3 tumors, >2 positive SLNs, invasive lobular carcinoma, estrogen receptor negative status, extranodal extension, Nottingham Grade 3, or were age <50 years. RESULTS: We identified 105 women treated between July 2011 and July 2016 with a median follow-up time of 48.5 months (Range, 11-83 months). There were 40 women with an extranodal extension (38.9%) and 42 women with grade 3 disease (40.0%). Nineteen patients received whole breast irradiation alone (18.1%) and 86 patients were treated with modified tangent fields including the superior axilla level I/II (81.9%). Thirty-three patients (31.4%) also received a 3rd supraclavicular, nodal-directed field. Among the 86 patients who received axillary nodal irradiation, nodal volume contouring was performed in 77 patients (89.5%). Fifty-one patients (48.6%) also received adjuvant chemotherapy. The overall rates of 4-year DFS and locoregional control (LRC) were 94.3% and 98.1%, respectively. Off all patients, 1 patient experienced an internal mammary nodal recurrence, another patient a contralateral breast tumor, and two patients distant metastases. There were no axillary or ipsilateral breast tumor recurrences. CONCLUSIONS: This retrospective analysis of women who were underrepresented or excluded from the Z11 trial and underwent a lumpectomy and SLN biopsy with positive SLNs demonstrated comparable rates of LRC and DFS. The high rates of LRC and DFS suggest that completion ALND may be safely omitted in this patient population but larger data sets and longer follow-up times are needed to confirm this finding.
引用
- Gebhardt BJ, Thomas J, Horne ZD, et al. Is completion axillary lymph node dissection necessary in patients who are underrepresented in the ACOSOG Z0011 trial? Adv Radiat Oncol. 2018. PMID: 30197938. doi:10.1016/j.adro.2018.03.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。